viewPressure BioSciences, Inc.

Pressure BioSciences expecting banner year for the company in 2018

Revenues for the firm's products and services increased 21% in the third quarter alone

pressure gauge
The firm speciaises in PCT (pressure cycling technology)

Pressure BioSciences Inc's (OTCMKTS:PBIO) boss Richard Schumacher expects 2018 to be a “banner year” for the firm.

In a 'Stock Day' podcast Schumacher ran through a number of aspects of recent progress, including that it had sold more PCT (pressure cycling technology) machines in the third quarter of 2017 than it had ever sold in a single quarter before.

Revenues for the firm's products and services increased 21% in that quarter alone, with consumable products increasing 158% - the largest increase in consumables the firm ever reported.

Schumacher also said a big multinational company, who was a customer, had also been working with Pressure to produce a software upgrade for its flagship Barocycler 2320EXTREME instrument.

Pressure believes this new instrument will now be "highly desirable" in its niche life sciences and pharmaceutical markets.

Also discussed was the newly established Center of Excellence in China, which will showcase three of the company's PCT instruments and many related consumable products.

"Being the first Center of Excellence in Asia, the company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements," said Schumacher.

The firm's acquisition of BaroFold Inc had increased the IP (intellectual property) estate of the company by eight issued and several pending patents, and had allowed the company to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation, he added.

Watch the Podcast HERE...

Quick facts: Pressure BioSciences, Inc.

Price: 2.13 USD

Market: OTCQB
Market Cap: $6.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...


2 min read